Healthcare Value-Creators Jim Pearson and Joseph Mark Reunite to Scale HoloMD’s AI-Powered Psychiatry Platform

Audio By Carbonatix

BETHESDA, Md.--(BUSINESS WIRE)--Oct 28, 2025--

HoloMD, the AI-powered remote therapeutic monitoring (RTM) platform for psychiatry, today announced the appointment of veteran med-tech operator Jim Pearson as Executive Chairman, reuniting him with longtime collaborator Joseph (“Joe”) Mark, a Director on HoloMD’s Board. This marks the pair’s third partnership building category-defining healthcare companies that have delivered strong investor returns—following successful outcomes at Suros Surgical Systems and NICO Corporation.

“Joe and I have a 20-year history of taking on hard clinical problems and turning them into scalable businesses that improve patient care,” said Pearson. “HoloMD is our most meaningful challenge yet: applying human-supervised AI to expand access, raise care quality, and support clinicians at a time when behavioral health demand vastly exceeds supply.”

“We’ve built companies that improved outcomes and generated compelling returns,” added Mark. “HoloMD applies the same disciplined playbook—clinical rigor, human oversight, and scalable technology—to behavioral health.”

“I’m elated to work with Jim and Joe every day to scale HoloMD into the leading AI-powered behavioral health platform,” said Bruce Alan Kehr, MD, Founder and CEO of HoloMD. “Their proven ability to turn breakthrough ideas into extraordinary shareholder value—and our shared passion for improving mental health care—make this an exceptional opportunity to meet soaring demand and help patients in need.”

Why HoloMD Now

Mental health remains one of healthcare’s greatest unmet needs. Millions of patients struggle in silence between appointments, clinicians are overextended, and systems absorb rising costs. HoloMD addresses this gap with a clinically led, human-in-the-loop AI platform anchored by Dr. Holo™—a virtual psychiatric assistant designed to conduct an initial intake, extend it across 190 empathy-mapped contexts, and continuously monitor care-plan and medication adherence.

The result is ongoing, personalized support for patients and visit-ready insights for clinicians, delivered safely and at scale.

The AI-Powered Advantage

HoloMD’s AI-powered platform delivers measurable value across the healthcare ecosystem, enhancing outcomes for patients, insight for providers, and efficiency for organizations and payers.

• Patients: Personalized daily engagement that adapts to each individual. Dr. Holo learns every patient’s goals, symptoms, and barriers from intake onward—then tailors check-ins, education, and empathetic nudges to sustain care-plan and medication adherence. Patients feel seen between visits and arrive with a clear story of progress and challenges—insight impossible without AI-scaled, human-reviewed conversation that deepens connection and continuity.
• Providers: A between-visit lens on the human behind the symptoms, summarized by AI for review during the clinic visit. While in-session with the patient, providers receive concise AI summaries of daily and weekly interactions, highlighting adherence, symptom, and mood trends. These summaries turn fragmented exchanges into actionable intelligence, helping providers understand patients at a deeper level and focus precious time where it drives outcomes.
• Provider Organizations (Owners/Health Systems): Standardized quality at scale with RTM-driven economics. Human-supervised AI automates intake, adherence tracking, and documentation — creating consistent workflows, repeatable outcomes, and audit-ready records. Leaders gain visibility across cohorts and sites, improving efficiency and revenue growth without adding headcount.
• Payers & Systems: Actionable intelligence that helps lower total cost of care. AI-curated data flags identify risk early, support timely intervention, and strengthen adherence to evidence-based treatment plans. The platform aims to reduce avoidable hospitalizations while improving member experience and quality metrics, delivering real-time visibility across populations through AI orchestration with human oversight.

Strategic Leadership to Drive Scale

As Executive Chairman, Pearson will lead capital formation, customer execution, operational discipline, and team growth. HoloMD is led by Dr. Kehr, a nationally recognized psychiatrist whose vision blends decades of clinical experience with cutting-edge technology to extend care beyond the appointment—and reach more patients when and where they need it most.

About HoloMD

HoloMD has brought to market a patent-pending AI-powered psychiatry platform that augments clinicians with continuous, human-supervised patient engagement—spanning intake, treatment adherence, and RTM-aligned workflows - to provide mission-critical information designed to improve outcomes and reduce costs. Founded in July 2024, the company is fully HIPAA- and HITECH-compliant, supports Medicare RTM billing, and currently has seven provisional and one utility patents pending and three trademarks pending. Learn more at HoloMD.ai.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251028597093/en/

CONTACT: Investor and Media Contact

Idea Grove

[email protected]

KEYWORD: MARYLAND UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: MENTAL HEALTH TECHNOLOGY HOSPITALS HEALTH TECHNOLOGY SOFTWARE OTHER HEALTH GENERAL HEALTH HEALTH DATA MANAGEMENT ARTIFICIAL INTELLIGENCE

SOURCE: HoloMD

Copyright Business Wire 2025.

PUB: 10/28/2025 09:07 AM/DISC: 10/28/2025 09:07 AM

http://www.businesswire.com/news/home/20251028597093/en